InvestSMART

Dimerix Limited (ASX:DXB)

ALERT: Price-sensitive ASX Announcement for DXB
Current share price for DXB : $0.240 -0.235 (-49.47%)+
Announcement
Release
28 Aug 2025 9:06AM
Price at Release
$0.475
Full Release
download
Summary
Dimerix Limited's 2025 Annual Report and Appendix 4E reveal significant developments and financial outcomes for the financial year ending June 30, 2025. The company reported total revenue of $5,586,828, largely attributed to the licensing fees and a milestone payment from Fuso Pharmaceutical Industries. Despite this, the company experienced a net loss of $13,251,722 after a substantial income tax benefit. Key financial moves included the issuance of 2,700,000 options to directors and a significant increase in research and development expenses to $27,323,617. The company's capital management strategy remains focused on sustaining operations and optimizing equity returns. Dimerix's share-based payment reserve increased due to new grants, and the company did not declare any dividends. The financial position of Dimerix showed total assets of $91,177,104 with a net equity of $13,379,343. The report highlights the internal transfer of license-related assets to a subsidiary to streamline operations and revenue recognition.
Key Points
  • Total revenue of $5,586,828 largely from licensing fees.
  • Net loss of $13,251,722 after income tax benefit.
  • Issued 2,700,000 options to directors.
  • Research and development expenses rose to $27,323,617.
  • Capital management strategy focused on sustaining operations.
  • Share-based payment reserve increased due to new grants.
  • No dividends declared.
  • Total assets of $91,177,104 and net equity of $13,379,343.
  • Internal transfer of license-related assets to a subsidiary.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.